# Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

> **NCT02501213** · PHASE2 · TERMINATED · sponsor: **Centre Oscar Lambret** · enrollment: 14 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Spironolactone (+/- Furosemide)

## Key facts

- **NCT ID:** NCT02501213
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-30
- **Primary completion:** 2017-11-23
- **Final completion:** 2018-12-24
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501213, "Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02501213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*